Special Drug-Use Results Survey of IMBRUVICA Capsules 140 mg (relapsed or refractory mantle cell lymphoma [MCL])
Not Applicable
- Conditions
- Relapsed or refractory mantle cell lymphoma
- Registration Number
- JPRN-UMIN000028130
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
NA
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety(Adverse Drug Reaction) Effectiveness
- Secondary Outcome Measures
Name Time Method